SMi Source Lesson Anticoagulation: Thienopyridines

  • SMi Source lesson Anticoagulation: Thienopyridines has the following microlearning topics

  • 1. Learning Objectives

    2. Thienopyridines: Introduction

    3. Introduction: ADP P2Y12 Receptor Antagonists

    4. Introduction: Thienopyridines

    5. Ticlopidine: Overview

    6. Ticlopidine: Mechanism of Action

    7. Ticlopidine: Approved Indications

    8. Ticlopidine: Boxed Warning

    9. Ticlopidine: Warnings

    10. Replaced by Clopidogrel

    11. Clopidogrel: Mechanism of Action

    12. Clopidogrel: Approved Indications

    13. Clopidogrel: Dosage and Administration

    14. Clopidogrel: Warnings

    15. Clopidogrel: Warnings

    16. Drug Interactions and Hyporesponse

    17. Genetic Variation

    18. Registration Studies

    19. CAPRIE

    20. CAPRIE: Conclusion

    21. CURE Study

    22. COMMIT Study

    23. CLARITY Study

    24. PCI Studies

    25. PCI-CURE Study

    26. PCI-CLARITY Study

    27. High Loading Dose Studies

    28. CURRENT-OASIS 7 Study

    29. CURRENT-OASIS 7: Results

    30. ISAR CHOICE Study

    31. ALBION Study

    32. ARMYDA-2 Study

    33. ARMYDA-2: Conclusion

    34. Pretreatment Study

    35. CREDO Study

    36. CREDO: Conclusion

    37. Non-ACS (including Stroke) Studies

    38. CARESS Study

    39. CARESS: Results

    40. MATCH Study

    41. MATCH: Conclusion

    42. CHARISMA Study

    43. CHARISMA: Asymptomatic and Symptomatic

    44. Prasugrel: Mechanism of Action

    45. Prasugrel: Mechanism of Action

    46. Approved Indications

    47. Dosage and Administration

    48. Boxed Warnings

    49. JUMBO-TIMI 26 Study

    50. JUMBO TIMI 26: Results

    51. TRITON-TIMI 38 Clinical Trial

    52. Objectives: Testing the Hypothesis

    53. Objectives: Primary Endpoints

    54. Primary Efficacy and Safety Data

    55. Primary Efficacy and Safety Data: Net Clinical Benefit and Conclusion

    56. Stent Thrombosis Sub-Analysis

    57. Stent Thrombosis Sub-Analysis: Results and Conclusion

    58. Early and Late Events (Landmark Analysis): Study Design

    59. Early and Late Events (Landmark Analysis)

    60. Recurrent Events Data

    61. Recurrent Events Data: Results and Conclusion

    62. STEMI Population Data

    63. STEMI Population Data: Conclusion

    64. MI Analysis (Including Universal Definition)

    65. MI Analysis (Including Universal Definition): Results

    66. MI Analysis (Including Universal Definition)

    67. Diabetes Data

    68. Diabetes Data: Conclusion

    69. PRINCIPLE-TIMI 44 Study

    70. PRINCIPLE-TIMI 44: Results and Conclusion

    71. Variability of Response: IPA Link to Clinical Outcomes

    72. Differences in Active Metabolite Generation

    73. Comparative PK/PD

    74. Comparative PK/PD: Clinical Implications

    75. Key Differences in Plavix® and Effient™ Label